• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Acta Pharmacol Sin . Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails

tetano

Editor, Senior Moderator
Acta Pharmacol Sin


. 2023 Jan 27;1-9.
doi: 10.1038/s41401-022-01043-w. Online ahead of print.
Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails


Hang Ma[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Hui-Fang Zong[SUP] #[/SUP][SUP] 1 2 4 [/SUP], Jun-Jun Liu[SUP] #[/SUP][SUP] 1 2 [/SUP], Ya-Li Yue[SUP] #[/SUP][SUP] 1 2 [/SUP], Yong Ke[SUP] 1 2 [/SUP], Yun-Ji Liao[SUP] 1 2 [/SUP], Hao-Neng Tang[SUP] 1 2 [/SUP], Lei Wang[SUP] 1 2 [/SUP], Shu-Sheng Wang[SUP] 5 [/SUP], Yun-Sheng Yuan[SUP] 1 2 [/SUP], Ming-Yuan Wu[SUP] 1 2 [/SUP], Yan-Lin Bian[SUP] 1 2 [/SUP], Bao-Hong Zhang[SUP] 1 2 [/SUP], Hai-Yang Yin[SUP] 1 2 [/SUP], Hua Jiang[SUP] 5 [/SUP], Tao Sun[SUP] 6 7 [/SUP], Lei Han[SUP] 8 [/SUP], Yue-Qing Xie[SUP] 9 [/SUP], Jian-Wei Zhu[SUP] 10 11 [/SUP]



Affiliations
Free PMC article

Abstract

The continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses challenges to the effectiveness of neutralizing antibodies. Rational design of antibody cocktails is a realizable approach addressing viral immune evasion. However, evaluating the breadth of antibody cocktails is essential for understanding the development potential. Here, based on a replication competent vesicular stomatitis virus model that incorporates the spike of SARS-CoV-2 (VSV-SARS-CoV-2), we evaluated the breadth of a number of antibody cocktails consisting of monoclonal antibodies and bispecific antibodies by long-term passaging the virus in the presence of the cocktails. Results from over two-month passaging of the virus showed that 9E12 + 10D4 + 2G1 and 7B9-9D11 + 2G1 from these cocktails were highly resistant to random mutation, and there was no breakthrough after 30 rounds of passaging. As a control, antibody REGN10933 was broken through in the third passage. Next generation sequencing was performed and several critical mutations related to viral evasion were identified. These mutations caused a decrease in neutralization efficiency, but the reduced replication rate and ACE2 susceptibility of the mutant virus suggested that they might not have the potential to become epidemic strains. The 9E12 + 10D4 + 2G1 and 7B9-9D11 + 2G1 cocktails that picked from the VSV-SARS-CoV-2 system efficiently neutralized all current variants of concern and variants of interest including the most recent variants Delta and Omicron, as well as SARS-CoV-1. Our results highlight the feasibility of using the VSV-SARS-CoV-2 system to develop SARS-CoV-2 antibody cocktails and provide a reference for the clinical selection of therapeutic strategies to address the mutational escape of SARS-CoV-2.

Keywords: SARS-CoV-2; antibody; neutralization; variant; vesicular stomatitis virus.
 
Back
Top Bottom